Valuation : CervoMed Inc.

Market Cap 38.86M 33.53M 31.75M 28.74M 53.9M 3.71B 54.29M 375M 145M 1.89B 146M 143M 5.97B P/E 2026 *
-1.19x
P/E 2027 * -1.73x
Enterprise Value -120M -104M -98.09M -88.78M -167M -11.47B -168M -1.16B -447M -5.83B -451M -441M -18.45B EV / Sales 2026 *
-900x
EV / Sales 2027 * -95.3x
Free-Float
73.57%
Yield 2026 *
-
Yield 2027 * -
1 day+3.63%
1 week+0.39%
Current month-2.28%
1 month-16.29%
3 months+4.90%
6 months-40.65%
Current year-67.47%
1 week 2.42
Extreme 2.4199
2.64
1 month 2.42
Extreme 2.4199
2.99
Current year 2.13
Extreme 2.13
8.22
1 year 2.13
Extreme 2.13
10
3 years 1.8
Extreme 1.8
26.38
5 years 1.8
Extreme 1.8
26.38
10 years 1.8
Extreme 1.8
26.38
Manager TitleAgeSince
Chief Executive Officer 64 2023-08-15
Director of Finance/CFO 42 2024-02-29
Chief Tech/Sci/R&D Officer 49 2025-05-31
Director TitleAgeSince
Director/Board Member 64 2023-08-15
Chairman 64 2018-03-31
Director/Board Member 68 2020-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
2/11/26 Free

Executive/Senior Manager

30,000 0.3242%
2/11/26 Free

Chief Financial Officer

30,000 0.3242%
2/11/26 Free

General Counsel

30,000 0.3242%
Change 5-day change 1-year change 3-year change Capi.($)
+3.63%+0.39%-70.96%-51.96% 38.86M
-2.11%-1.68%+43.40%+95.27% 66.93B
-0.23%-4.45%+32.50%+75.75% 61.97B
+1.67%+2.47%-11.32%+380.54% 28.26B
-1.05%-4.43%+28.84%+10.59% 24.59B
+0.34%-6.78%-0.01%-16.35% 24.3B
+0.43%-3.37%+16.22%-17.99% 19.41B
-3.03%-2.29%+181.72%+335.27% 16.77B
-1.94%-4.94%-8.15%+483.69% 14.18B
+3.24%-0.31%-7.34%+880.45% 14B
Average +0.10%-2.61%+20.49%+217.53% 27.05B
Weighted average by Cap. -0.56%-2.83%+31.24%+170.62%

Financials

2026 *2027 *
Net sales 133K 115K 109K 98.61K 185K 12.74M 186K 1.29M 497K 6.47M 501K 490K 20.49M 833K 719K 681K 616K 1.16M 79.62M 1.16M 8.05M 3.1M 40.47M 3.13M 3.06M 128M
Net income -28.98M -25.01M -23.68M -21.44M -40.21M -2.77B -40.49M -280M -108M -1.41B -109M -106M -4.45B -41.31M -35.65M -33.76M -30.55M -57.31M -3.95B -57.72M -399M -154M -2.01B -155M -152M -6.35B
Net Debt -159M -137M -130M -118M -220M -15.18B -222M -1.54B -592M -7.72B -597M -584M -24.42B -118M -102M -96.66M -87.49M -164M -11.3B -165M -1.14B -441M -5.75B -444M -434M -18.18B
Logo CervoMed Inc.
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Employees
15
Date Price Change Volume
26-09-11 US$2.570 +3.63% 234,572
26-09-10 US$2.480 -1.20% 114,864
26-09-09 US$2.510 -0.79% 156,009
26-09-08 US$2.530 -1.17% 393,938
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.570USD
Average target price
15.40USD
Spread / Average Target
+499.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRVO Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!